An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers

Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, et al. | PLoS One | 2017 | Evidence: moderate

View on PubMed → | DOI | Publisher

Plain-language summary

Published 2017 in PLoS One, this work by Airhart SE and collaborators tackles a specific question within safety-focused NMN/NAD+ research.

Key findings reported by the authors

Open-label, non-randomized human study of nicotinamide riboside (NR) pharmacokinetics in healthy volunteers (PLoS One, 2017)
Reported that oral NR raised blood NAD+ levels; note this studied NR, not NMN
Open-label design without a control group limits the strength of the evidence

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to safety decisions, with secondary relevance to compare. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index